Brief: Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd)
15/04/2025 12:04
April 15 (Reuters) - Mind Medicine (MindMed) Inc MNMD.O: MINDMED ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 EMERGE STUDY OF MM120 IN MAJOR DEPRESSIVE DISORDER (MDD) MIND MEDICINE (MINDMED) INC - TOPLINE DATA EXPECTED IN SECOND HALF OF 2026 Source text: ID:nBw5nGMWba Further company coverage: MNMD.O ((Reuters.Briefs@thomsonreuters.com;))